The KLK15 antibody is designed to target kallikrein-related peptidase 15 (KLK15), a serine protease encoded by the KLK15 gene. This enzyme is part of the human kallikrein family, comprising 15 secreted proteases (KLK1-KLK15) that play roles in tissue remodeling, hormone processing, and cancer progression. KLK15 is synthesized as an inactive zymogen, requiring proteolytic cleavage for activation. It is expressed in various tissues, including the prostate, breast, and ovaries, though its physiological functions remain less characterized compared to other kallikreins like KLK3 (PSA).
Research highlights KLK15's potential involvement in cancer, particularly hormone-related malignancies. Studies suggest KLK15 may influence signaling pathways linked to cell proliferation, angiogenesis, and metastasis. For example, elevated KLK15 expression has been observed in prostate and ovarian cancers, correlating with tumor aggressiveness or prognosis in some cohorts. However, its role appears context-dependent, with conflicting findings across cancer types.
KLK15 antibodies are primarily used as research tools to detect KLK15 protein expression in tissues or biological fluids via immunohistochemistry, Western blotting, or ELISA. These antibodies aid in elucidating KLK15's biomarker potential, therapeutic relevance, or mechanistic contributions to disease. Commercial KLK15 antibodies vary in specificity, often validated for cross-reactivity within the KLK family. Ongoing research aims to clarify its biological significance and explore clinical applications, such as targeted therapies or diagnostic assays.